Lineage Cell Therapeutics’ (LCTX) “Buy” Rating Reiterated at HC Wainwright

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $9.00 price objective on the stock.

A number of other equities analysts also recently weighed in on LCTX. D. Boral Capital lowered their target price on shares of Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Tuesday. Maxim Group cut their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX opened at $0.64 on Tuesday. Lineage Cell Therapeutics has a 12 month low of $0.48 and a 12 month high of $1.61. The stock has a market cap of $141.29 million, a price-to-earnings ratio of -5.34 and a beta of 1.21.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Hedge funds have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of Lineage Cell Therapeutics in the third quarter worth about $46,000. Defender Capital LLC. grew its stake in Lineage Cell Therapeutics by 0.6% in the 3rd quarter. Defender Capital LLC. now owns 5,002,198 shares of the company’s stock worth $4,528,000 after buying an additional 29,223 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Lineage Cell Therapeutics in the 3rd quarter worth $84,000. MAI Capital Management increased its holdings in shares of Lineage Cell Therapeutics by 2.2% in the 3rd quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock worth $1,516,000 after buying an additional 35,907 shares during the last quarter. Finally, Raffles Associates LP raised its position in shares of Lineage Cell Therapeutics by 3.4% during the 3rd quarter. Raffles Associates LP now owns 4,507,781 shares of the company’s stock valued at $4,081,000 after buying an additional 150,000 shares in the last quarter. Institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.